Todd C. Davis - 25 Mar 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Executive Officer, Director
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Issuer symbol: LGND
Transactions as of: 25 Mar 2024
Net transactions value: +$919,147
Form type: 4
Filing time: 27 Mar 2024, 17:47:59 UTC
Previous filing: 29 Feb 2024
Next filing: 18 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Options Exercise	$344,098	+7,448	+7.2%	$46.20	111,593	25 Mar 2024	Direct
transaction	LGND	Common Stock	Options Exercise	$191,970	+2,855	+2.6%	$67.24	114,448	25 Mar 2024	Direct
transaction	LGND	Common Stock	Options Exercise	$147,708	+2,156	+1.9%	$68.51	116,604	25 Mar 2024	Direct
transaction	LGND	Common Stock	Options Exercise	$235,372	+3,556	+3%	$66.19	120,160	25 Mar 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-7,448	-100%	$0.000000^*	0	25 Mar 2024	Common Stock	7,448	$46.20	Direct	F1
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-3,556	-100%	$0.000000^*	0	25 Mar 2024	Common Stock	3,556	$66.19	Direct	F2
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,855	-100%	$0.000000^*	0	25 Mar 2024	Common Stock	2,855	$67.24	Direct	F3
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,156	-100%	$0.000000^*	0	25 Mar 2024	Common Stock	2,156	$68.51	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023.
F2	This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F3	This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F4	This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.